# Effect of Privigen Against Graft Loss

> **NCT02374736** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 18 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Privigen (Human normal immunoglobulin G (IgG > 98 % purity))

## Key facts

- **NCT ID:** NCT02374736
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-05
- **Primary completion:** 2018-03-09
- **Final completion:** 2019-05-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02374736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02374736, "Effect of Privigen Against Graft Loss". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02374736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*